Clinical trial
Vaccine Therapy in Treating Patients With Breast Cancer
NCT00004156 · Memorial Sloan Kettering Cancer Center, Other · Completed
Key facts
| NCT number | NCT00004156 |
|---|---|
| Title | Vaccine Therapy in Treating Patients With Breast Cancer |
| Official title | Vaccination of High Risk Breast Cancer Patients With MUC-1 (Glycosylated) Keyhole Limpet Hemocyanin Conjugates Plus the Immunological Adjuvant QS21 |
| Lead sponsor | Memorial Sloan Kettering Cancer Center, Other |
| Collaborators | National Cancer Institute (NCI) NIH |
| Status | Completed |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | Breast Cancer |
| Intervention type | Biological |
| Interventions | MUC1-KLH vaccine/QS21 |
| Enrollment | 45 |
| Start date | May 1, 1999 |
| Primary completion | Jun 1, 2008 |
| First posted | May 20, 2004 |
| Last update posted | Oct 30, 2013 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: